baltimore conference logo
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Comparing Two Doses of Ipilimumab

April 22, 2015
Ahmad Tarhini, MD, PhD

Special Reports, Melanoma (Issue 4), Volume 4, Issue 1

Ahmad Tarhini, MD, PhD, associate professor, University of Pittsburgh School of Medicine, compares two doses of ipilimumab (Yervoy).

Ahmad Tarhini, MD, PhD, associate professor, University of Pittsburgh School of Medicine, compares two doses of ipilimumab (Yervoy).

<<<

Back to the Melanoma Special Report